Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
United States Aeglea Biotherapeutics Anthony Quinn Jonathan Alspaugh Exchange Commission European Medicines Agency
Source: prnewswire.com